Clinical Trial Update: Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dabigatran as an alternative anticoagulant in patients with left ventricular assist devices was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Dabigatran (Dabigatran etexilate)

Snippet

Sponsor: Daniel Zimpfer, MD | Conditions: Thrombosis, Bleeding | Phase 2 | Status: TERMINATED